ong term follow up of the immunogenicity of 7-valent pneumococcal conjugate vaccine (PCV7) in vulnerable elderly populations at high risk for invasive pneumococcal disease
Not Applicable
Completed
- Conditions
- ong term Immunity to Pneumococcal VaccinesLong term immunity to pcv7 and ppv13Long term Immunity to Pneumococcal VaccinesInfection - Other infectious diseasesInflammatory and Immune System - Normal development and function of the immune system
- Registration Number
- ACTRN12613001244796
- Lead Sponsor
- The Children's Hospital at Westmead. National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 136
Inclusion Criteria
Surviving subjects from the community who have previously participated in a completed trial of pneumococcal vaccines in frail elderly people when they were admitted to Westmead hospital between 2005-2007( Trial registration number ACTRN12607000387426)
Exclusion Criteria
Not being able or refuse to provide a blood sample
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determine trends in total functional antibody levels following 23PPV or PCV7 in a vulnerable elderly population by serum assay analysis[Five years and ten years after the final follow-up in the previously completed trial];Determine trends in total functional antibody levels following 23PPV or PCV7 in a vulnerable elderly population by serum assay analysis[five years and ten years after the final follow-up in the previously completed trial.]
- Secondary Outcome Measures
Name Time Method changes over time in the frailty index <br>[5 years and 10 years after the final follow-up in the previously completed trial];Readmission rates after the final follow-up[6 months and 5 years after the final follow-up in the previously completed trial]